Rural Health
Resources by Topic: Pharmacy and prescription drugs
Growth in the 340B Drug Pricing Program
Explores trends in drug purchases through the 340B program between 2010-2021. Discusses drugs purchased through the Prime Vendor Program, factors contributing to growth in the 340B program, and effects of the 340B program on the federal budget. Includes information on the growth of 340B Program participation by hospitals in Medicaid expansion and non-expansion states by Critical Access Hospital designation.
Additional links: Data Underlying Figures
Date: 09/2025
Sponsoring organization: Congressional Budget Office
view details
Explores trends in drug purchases through the 340B program between 2010-2021. Discusses drugs purchased through the Prime Vendor Program, factors contributing to growth in the 340B program, and effects of the 340B program on the federal budget. Includes information on the growth of 340B Program participation by hospitals in Medicaid expansion and non-expansion states by Critical Access Hospital designation.
Additional links: Data Underlying Figures
Date: 09/2025
Sponsoring organization: Congressional Budget Office
view details
The 340B Drug Discount Program: Litigation Topics and Trends
Provides an overview of the 340B Drug Discount Program. Discusses litigation surrounding the 340B program, including lawsuits against 340B-covered entities over their use of contract pharmacies to distribute 340B drugs to patients and lawsuits against states that have enacted laws to protect contract pharmacies and covered entities inside their state. Describes courts' interpretation of the 340B statute. Offers considerations for the 119th Congress in light of the litigation and describes several legislative changes that Congress could make to the program if it chose to do so.
Date: 09/2025
Sponsoring organization: Congressional Research Service
view details
Provides an overview of the 340B Drug Discount Program. Discusses litigation surrounding the 340B program, including lawsuits against 340B-covered entities over their use of contract pharmacies to distribute 340B drugs to patients and lawsuits against states that have enacted laws to protect contract pharmacies and covered entities inside their state. Describes courts' interpretation of the 340B statute. Offers considerations for the 119th Congress in light of the litigation and describes several legislative changes that Congress could make to the program if it chose to do so.
Date: 09/2025
Sponsoring organization: Congressional Research Service
view details
Medications for Opioid Use Disorder among Adults Who Had an Opioid Use Disorder
Offers National Survey on Drug Use and Health (NSDUH) data on adults receiving medications for opioid use disorder (MOUD) between 2022 and 2024 by age, sex, region, and metropolitan county status.
Date: 09/2025
Sponsoring organization: Substance Abuse and Mental Health Services Administration
view details
Offers National Survey on Drug Use and Health (NSDUH) data on adults receiving medications for opioid use disorder (MOUD) between 2022 and 2024 by age, sex, region, and metropolitan county status.
Date: 09/2025
Sponsoring organization: Substance Abuse and Mental Health Services Administration
view details
Fill Patterns of Glucose-Lowering Drugs with Cardiovascular and Kidney Benefits in the Rural and Urban United States, 2012–2021
Analyzes fill rates for GLP1RA and SGLT2i glucose-lowering drugs among people with type 2 diabetes by level of rurality and other demographics, utilizing 2012-2021 OptumLabs Data Warehouse claims data. Discusses how geographic differences in prescribing may influence cardiovascular and kidney disease outcomes among people with type 2 diabetes.
Author(s): Kyle Steiger, Kavya Sindhu Swarna, Jeph Herrin, Rozalina G. McCoy
Citation: Journal of General Internal Medicine, 41, 126-133
Date: 08/2025
view details
Analyzes fill rates for GLP1RA and SGLT2i glucose-lowering drugs among people with type 2 diabetes by level of rurality and other demographics, utilizing 2012-2021 OptumLabs Data Warehouse claims data. Discusses how geographic differences in prescribing may influence cardiovascular and kidney disease outcomes among people with type 2 diabetes.
Author(s): Kyle Steiger, Kavya Sindhu Swarna, Jeph Herrin, Rozalina G. McCoy
Citation: Journal of General Internal Medicine, 41, 126-133
Date: 08/2025
view details
Pharmacy Barriers to Receiving Buprenorphine among Patients Undergoing Telemedicine Addiction Treatment
Presents a study exploring pharmacy-level barriers experienced by patients with opioid use disorder who are receiving treatment via telemedicine. Discusses barriers that lead to missed doses or inaccessible prescriptions. Breaks down data by health and demographic characteristics, such as age, education, and insurance type, among others, and whether the patient lived in a rural or nonrural area.
Author(s): Lauren E. Hendy, Lucas G. Hill, Amanda Olguin, et al.
Citation: JAMA Network Open, 8(8), e2527418
Date: 08/2025
view details
Presents a study exploring pharmacy-level barriers experienced by patients with opioid use disorder who are receiving treatment via telemedicine. Discusses barriers that lead to missed doses or inaccessible prescriptions. Breaks down data by health and demographic characteristics, such as age, education, and insurance type, among others, and whether the patient lived in a rural or nonrural area.
Author(s): Lauren E. Hendy, Lucas G. Hill, Amanda Olguin, et al.
Citation: JAMA Network Open, 8(8), e2527418
Date: 08/2025
view details
Prescribed Medications for Patients with Amphetamine-Type Stimulant Use Disorder Seen in Rural-Serving Pacific Northwest Primary Care Clinics
Examines the frequency in which patients living in the rural Pacific Northwest with amphetamine-type stimulant use disorder (AT-StUD) received medications for AT-StUD in primary care clinics. Utilizes 2017-2021 electronic health record (EHR) data to analyze patients who have received prescriptions according to demographics, mental health status, and health behaviors.
Author(s): Megan J. Yerton, Connor J. McCabe, Matthew D. Iles-Shih, Judith I. Tsui, Kevin A. Hallgren
Citation: Addiction Science & Clinical Practice, 20, 67
Date: 08/2025
view details
Examines the frequency in which patients living in the rural Pacific Northwest with amphetamine-type stimulant use disorder (AT-StUD) received medications for AT-StUD in primary care clinics. Utilizes 2017-2021 electronic health record (EHR) data to analyze patients who have received prescriptions according to demographics, mental health status, and health behaviors.
Author(s): Megan J. Yerton, Connor J. McCabe, Matthew D. Iles-Shih, Judith I. Tsui, Kevin A. Hallgren
Citation: Addiction Science & Clinical Practice, 20, 67
Date: 08/2025
view details
Rural Beneficiary Access to Medicare Advantage-Part D Plans
Policy brief updating RUPRI's analysis of Medicare Advantage-Part D plans (MA-PDs) including enhanced benefit plan availability and differences in characteristics across metropolitan, micropolitan, and noncore areas. Features statistics including number of MA-PDs and stand-alone prescription drug plans (PDPs), average monthly premium costs, and availability in metropolitan, micropolitan, and noncore areas from 2008-2023.
Author(s): Edmer Lazaro, Dan M. Shane, Fred Ullrich, Keith Mueller
Date: 08/2025
Sponsoring organization: RUPRI Center for Rural Health Policy Analysis
view details
Policy brief updating RUPRI's analysis of Medicare Advantage-Part D plans (MA-PDs) including enhanced benefit plan availability and differences in characteristics across metropolitan, micropolitan, and noncore areas. Features statistics including number of MA-PDs and stand-alone prescription drug plans (PDPs), average monthly premium costs, and availability in metropolitan, micropolitan, and noncore areas from 2008-2023.
Author(s): Edmer Lazaro, Dan M. Shane, Fred Ullrich, Keith Mueller
Date: 08/2025
Sponsoring organization: RUPRI Center for Rural Health Policy Analysis
view details
NCHS Rapid Surveys System: GLP-1 Medication Access and Use
Interactive data showing access to and use of GLP-1 medications. Includes data breakdown by prescriber and various patient characteristics including urbanicity. Data gathered by the National Center for Health Statistics in July and August 2025.
Date: 07/2025
Sponsoring organization: National Center for Health Statistics
view details
Interactive data showing access to and use of GLP-1 medications. Includes data breakdown by prescriber and various patient characteristics including urbanicity. Data gathered by the National Center for Health Statistics in July and August 2025.
Date: 07/2025
Sponsoring organization: National Center for Health Statistics
view details
The Uncertain Future of Medicare's Stand-Alone Prescription Drug Plan Market and Why It Matters
Discusses the Medicare Part D stand-alone prescription drug plan (PDP) market and the Part D premium stabilization demonstration. Describes the impact of PDP market stability on rural Medicare beneficiaries. Explores the potential effects of the continuation of, or changes to, the premium stabilization program.
Author(s): Juliette Cubanski, Tricia Neuman
Date: 07/2025
Sponsoring organization: KFF
view details
Discusses the Medicare Part D stand-alone prescription drug plan (PDP) market and the Part D premium stabilization demonstration. Describes the impact of PDP market stability on rural Medicare beneficiaries. Explores the potential effects of the continuation of, or changes to, the premium stabilization program.
Author(s): Juliette Cubanski, Tricia Neuman
Date: 07/2025
Sponsoring organization: KFF
view details
Mapping Healthcare Deserts: Over 80% of the Country Still Lacks Adequate Access to Healthcare
Provides information on healthcare and pharmacy deserts in the United States. Includes an interactive county-level U.S. map that shows healthcare deserts in the following categories: pharmacy, primary care, hospital, hospital beds, trauma center, and health center.
Author(s): Amanda Nguyen
Date: 07/2025
Sponsoring organization: GoodRx
view details
Provides information on healthcare and pharmacy deserts in the United States. Includes an interactive county-level U.S. map that shows healthcare deserts in the following categories: pharmacy, primary care, hospital, hospital beds, trauma center, and health center.
Author(s): Amanda Nguyen
Date: 07/2025
Sponsoring organization: GoodRx
view details